Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Slides:

Advertisements

Similar presentations

Giancarlo Agnelli Università di Perugia Anticoagulant treatment for PE: optimal duration.

Advertisements

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

Results: 1.Progression of thrombus length and volume (40% vs. 28%; P

Epidemiology of VTE in Patients with Cancer Paolo Prandoni, MD, PhD University of Padua (Italy) ESMO, Stockholm 2008.

DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?

Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline.

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,

Volume 149, Issue 5, Pages (May 2016)

Volume 130, Issue 6, Pages (December 2006)

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use by Ida Martinelli, Anthonie W. A. Lensing, Saskia.

Recurrent thromboembolism in patients with vena cava filters

Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology by Mary Cushman,

A Systematic Review On Different Prothrombin Complex Concentrate Strategies To Reverse Vitamin K Antagonist Therapy by Nakisa Khorsand, Hilde A.M. Kooistra,

How I treat elderly patients with myeloma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Catheter-related deep venous thrombosis in children with hemophilia

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,

Genetic sequence analysis of inherited bleeding diseases

New Oral Anticoagulants and VTE Management

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

by Alexander Röth, Andreas Hüttmann, Russell P

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

A Better Solution For Cancer Patients With VTE?

Imatinib for refractory chronic graft-versus-host disease with fibrotic features by Attilio Olivieri, Franco Locatelli, Marco Zecca, Adele Sanna, Michele.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Symptomatic venous thromboembolism after femoral vein harvest

Volume 154, Issue 6, Pages (December 2018)

Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk.

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Extraordinary Cases of VTE Prevention in Patients With Cancer

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

A Systematic Review of Pulmonary Embolism in Patients With Lung Cancer

Anticoagulation and Thrombosis Management

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

Cancer-Associated Thrombosis

by Alex C. Spyropoulos, and James D. Douketis

References: What is the connection between VTE and active cancer? 1. Khorana AA, Francis CW, Culakova E et al. Thromboembolism.

Variation in thromboembolic complications among patients undergoing commonly performed cancer operations Randall R. De Martino, MD, MS, Philip P. Goodney,

How I treat cancer-associated venous thromboembolism

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Recurrent thromboembolism in patients with vena cava filters

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

References: Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al.

Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study by Inger Lise Gade, Signe Juul Riddersholm, Ilse Christiansen,

Clive Kearon, Michael J Kovacs, Jim A Julian

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis by Rasha Khatib, Maja Ludwikowska, Daniel.

American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism by Wendy Lim, Grégoire Le.

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Balancing bleeding in brain metastases

New concepts for anticoagulant therapy in persons with hemophilia

Presentation transcript:

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni, Anthonie W. A. Lensing, Andrea Piccioli, Enrico Bernardi, Paolo Simioni, Bruno Girolami, Antonio Marchiori, Paola Sabbion, Martin H. Prins, Franco Noventa, and Antonio Girolami Blood Volume 100(10):3484-3488 November 15, 2002 ©2002 by American Society of Hematology

Cumulative incidence of recurrent VTE during anticoagulant therapy. Paolo Prandoni et al. Blood 2002;100:3484-3488 ©2002 by American Society of Hematology

Cumulative incidence of clinically important bleeding during anticoagulant therapy in DVT patients with and without cancer. Cumulative incidence of clinically important bleeding during anticoagulant therapy in DVT patients with and without cancer. Paolo Prandoni et al. Blood 2002;100:3484-3488 ©2002 by American Society of Hematology